In this study, pBD2 inhibited the DEGs in the proteasome, and even lowered some ubiquitin expression including UBB (polyubiquitin-B), NEDD8, UBE2J2 (ubiquitin-conjugating enzyme E2 J2), APC2 and APC11 (anaphase-promoting complex subunit 2 and 11), proteasomal ubiquitin receptor UCHL3 (ubiquitin carboxyl-terminal hydrolase isozyme L3), USP19 (ubiquitin carboxyl-terminal hydrolase 19) genes, etc., all perhaps further indicating that pBD2 inhibited inflammations and the occurrence of cancer, as discussed above. The gene discussed is ANAPC11; the disease is cancer.